No Data
格隆汇公告精选(港股)︱北海康成-B(01228.HK): CAN103, used to treat Gaucher's disease (GD), obtains priority review qualification.
【Today's Focus】Beihai Kangcheng-B (01228.HK): CAN103 for the treatment of Gaucher's Disease (GD) granted priority review qualification Beihai Kangcheng-B (01228.HK) announcement, CAN103 (Velaglucerase Beta) for the treatment of Gaucher's Disease (GD) has been granted priority review qualification by the National Medical Products Administration Drug Approval Center. The granting of priority review qualification to CAN103 (Velaglucerase Beta) recognizes the urgent medical needs of GD patients in china and the advantages of the company's clinical trial results. The company is making every effort to accelerate the approval process of CAN103 (Velaglucerase Beta) to make it the first one.
Top Education Group Reports Strong Annual Growth
Top Education Group Announces Year-End Dividend
TOP EDUCATION: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 30 JUNE 2024
Top Education Group Schedules Key Financial Meeting
Top Education (01752.HK) plans to hold a board of directors meeting on September 30th to approve the annual performance.
Gelonghui September 17th, top education (01752.HK) announced that the board of directors will hold a board meeting on September 30, 2024 (Monday) to consider and approve the annual full-year performance of the company and its subsidiaries as of June 30, 2024, as well as proposed final dividends (if any), and to deal with other matters.
Top Education Group Ltd (HKG:1752) Shares May Have Slumped 28% But Getting In Cheap Is Still UnlikelyNo Data
No Data
